Core Viewpoint - Achilles Therapeutics plc has announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister from the SEC as part of a planned liquidation process [1][2]. Group 1: Delisting and Deregistration - The company will file a Form 25 with the SEC on March 10, 2025, with the last trading day on Nasdaq expected to be March 20, 2025 [2]. - Following the delisting, trading of the company's ADSs will only occur in privately negotiated sales or potentially on an over-the-counter market, with no guarantee of continued trading [2]. - The company plans to file a Form 15 with the SEC around March 20, 2025, which will suspend its obligation to file periodic reports immediately and terminate it 90 days after the Form 15 is filed [3].
Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration